REDWOOD CITY, Calif., June 15, 2017 /PRNewswire/ — Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that Neurosurgery, the official journal of the Congress of Neurological Surgeons (CNS), selected the SENZA-RCT 24-month outcomes publication as the journal’s Top Pain Paper of the Year.  The SENZA-RCT is a groundbreaking pivotal study that was both the largest prospective randomized clinical trial ever conducted to assess the treatment of chronic back and leg pain, and the first to evaluate comparative effectiveness of spinal cord stimulation (SCS) therapies.

Each paper was subject to a rigorous review process with the journal’s editorial board, beginning with initial selection from the entire pool of papers published between June 2016 and June 2017.  “The CNS is committed to providing relevant and informative science to our members. This paper delivers on that commitment, and improves our field through innovation. This accomplishment is remarkable and should be celebrated,” said Dr. Alan M. Scarrow, CNS President.

Dr. Todd Sitzman first presented the 24-month results of the SENZA-RCT during the 2015 North American Neuromodulation Society (NANS) meeting.  The results showed the sustained superiority of HF10™ therapy versus traditional low-frequency SCS therapy across all primary and secondary endpoints—including pain relief in the back and legs, and functional outcomes at every evaluation point to 24 months.

The Principal Investigator of the trial, Dr. Leonardo Kapural, from Wake Forest University Baptist Medical Center, will present the trial results at the 2017 CNS Annual Meeting on Wednesday, October 11, in Boston, MA.  “We are excited to have our manuscript detailing the 24-month outcomes from the SENZA-RCT selected as the Top Pain Paper of the Year,” stated Dr. Kapural. “The aim of the study was to provide meaningful longitudinal, comparative evidence that will assist physicians in better evaluating therapies and determining the best course of treatment for their patients suffering from chronic pain.  It is humbling that our work received this prestigious award.”

“We are truly honored by this recognition from the prestigious Neurosurgery journal,” said Rami Elghandour, President and CEO of Nevro. “We believe comparative, prospective long-term RCTs serve as the cornerstone of advancing patient care.  We sincerely appreciate the editorial board’s recognition of the quality of work by Dr. Kapural and the SENZA-RCT investigators for their groundbreaking study.  We are continuing to invest in rigorous RCTs and look forward to increasing support for the field with pragmatic Level I evidence.”

Access to the full two-year SENZA-RCT publication, originally published in the December 2016 issue of Neurosurgery, can be found here:

About the Congress of Neurological Surgeons

The Congress of Neurological Surgeons is the global leader in neurosurgical education, serving to promote health by advancing neurosurgery through innovation and excellence in education. The CNS provides leadership in neurosurgery by inspiring and facilitating scientific discovery and its translation into clinical practice. The CNS maintains the vitality of the profession through volunteer efforts of its members and the development of leadership in service to the public, to colleagues in other disciplines, and to neurosurgeons throughout the world in all stages of their professional lives. For more information, visit

About Nevro

Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza® spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza system is the only SCS system that delivers Nevro’s proprietary HF10 therapy. Senza, HF10, Nevro and the Nevro logo are trademarks of Nevro.

Investor Relations Contact:
Nevro Investor Relations
Katherine Bock
(650) 433-3247



To view the original version on PR Newswire, visit:

SOURCE Nevro Corp.